2FV 株式概要 ScandiDos AB (publish)は、世界中のクリニックで実施されている新しい動的治療と変調治療の品質保証と検証のために設計された測定システムとソフトウェアの提供に従事しています。 詳細
価格と性能
の歴代最高値、変動、値下がりまとめScandiDos 過去の株価 現在の株価 SEK 0.11 52週高値 SEK 0.19 52週安値 SEK 0.10 ベータ 1.14 11ヶ月の変化 -5.93% 3ヶ月変化 -9.76% 1年変化 -17.47% 33年間の変化 -63.96% 5年間の変化 -66.92% IPOからの変化 -78.15%
最新ニュース ScandiDos AB (publ), Annual General Meeting, Oct 23, 2024 Sep 25
New minor risk - Shareholder dilution Sep 24
First quarter 2025 earnings released Sep 20
Full year 2024 earnings released: kr0.32 loss per share (vs kr0.20 loss in FY 2023) Jun 19 ScandiDos AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.243547 million. Mar 20
Third quarter 2024 earnings released Mar 13 最新情報をもっと見る ScandiDos AB (publ), Annual General Meeting, Oct 23, 2024 Sep 25
New minor risk - Shareholder dilution Sep 24
First quarter 2025 earnings released Sep 20
Full year 2024 earnings released: kr0.32 loss per share (vs kr0.20 loss in FY 2023) Jun 19 ScandiDos AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.243547 million. Mar 20
Third quarter 2024 earnings released Mar 13
New major risk - Financial position Jan 15
Second quarter 2024 earnings released Dec 13
First quarter 2024 earnings released Sep 15
New major risk - Market cap size Aug 17
Third quarter 2023 earnings released Mar 12
Now 24% undervalued after recent price drop Mar 08
Second quarter 2023 earnings released Dec 10
Forecast breakeven date pushed back to 2024 Nov 16
Forecast breakeven date pushed back to 2024 Sep 18
First quarter 2023 earnings released Sep 17
Full year 2022 earnings released: kr0.18 loss per share (vs kr0.034 loss in FY 2021) Jun 30
Third quarter 2022 earnings: Revenues miss analyst expectations Mar 13
ScandiDos Launches Delta4 Insight Which Is Immediately Available to Sell to Customers in Europe and Parts of Asia Feb 26
ScandiDos AB Ordinary Shares to Be Deleted from Other OTC Dec 23
Second quarter 2022 earnings: Revenues miss analyst expectations Dec 15
First quarter 2022 earnings released Sep 24
Forecast to breakeven in 2022 Sep 23
Full year 2021 earnings released: kr0.034 loss per share (vs kr0.32 loss in FY 2020) Jul 01
Third quarter 2021 earnings released: kr0.02 loss per share (vs kr0.039 loss in 3Q 2020) Mar 12
New 90-day high: €0.45 Jan 30
New 90-day high: €0.41 Jan 12
New 90-day high: €0.40 Dec 24
New 90-day high: €0.28 Dec 09 ScandiDos AB (publ) to Report Q3, 2021 Results on Mar 10, 2021
First quarter earnings released Sep 27
Full year earnings released - €0.32 loss per share Sep 16 株主還元 2FV DE Medical Equipment DE 市場 7D -10.5% -1.0% -0.02% 1Y -17.5% -7.3% 8.2%
株主還元を見る
業界別リターン: 2FV過去 1 年間で-7.3 % の収益を上げたGerman Medical Equipment業界を下回りました。
リターン対市場: 2FVは、過去 1 年間で8.2 % のリターンを上げたGerman市場を下回りました。
価格変動 Is 2FV's price volatile compared to industry and market? 2FV volatility 2FV Average Weekly Movement 14.9% Medical Equipment Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.9% 10% least volatile stocks in DE Market 2.4%
安定した株価: 2FVの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: 2FVの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。
会社概要 ScandiDos AB (publish)は、世界中のクリニックで実施されている新しいダイナミック治療や変調治療のQAと検証のために設計された測定システムとソフトウェアの提供に従事しています。VMAT、RapidArc、IMRT、Tomotherapyなどの先進放射線治療のQA用にDelta4 DiscoverとDelta4 Phantom+を提供している。同社は2001年に設立され、スウェーデンのウプサラに本社を置いている。
もっと見る ScandiDos AB (publ) 基礎のまとめ ScandiDos の収益と売上を時価総額と比較するとどうか。 2FV 基礎統計学 時価総額 €8.18m 収益（TTM） -€840.71k 売上高(TTM ) €5.50m
収益と収入 最新の決算報告書（TTM）に基づく主な収益性統計 2FV 損益計算書（TTM） 収益 SEK 63.19m 売上原価 SEK 14.39m 売上総利益 SEK 48.81m その他の費用 SEK 58.47m 収益 -SEK 9.67m
一株当たり利益（EPS） -0.17 グロス・マージン 77.23% 純利益率 -15.30% 有利子負債／自己資本比率 0%
2FV の長期的なパフォーマンスは？
過去の実績と比較を見る
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
